Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis

Vista senzilla d'ítem
dc.contributor.authorMontes Moreno, Santiago
dc.contributor.authorBatlle, Ana
dc.contributor.authorGonzález de Villambrosía, Sonia
dc.contributor.authorSánchez-Espiridión, Beatriz
dc.contributor.authorCereceda, Laura
dc.contributor.authorGonzález Barca, Eva
dc.contributor.authorPurroy, Noelia
dc.contributor.authorPardal, Emilia
dc.contributor.authorMartín, Alejandro
dc.contributor.authorGrande, Carlos
dc.contributor.authorMazorra, Francisco
dc.contributor.authorInsunza, Andrés
dc.contributor.authorQuero, Cristina
dc.contributor.authorAguiar Bujanda, David
dc.contributor.authorCruz, Miguel Ángel
dc.contributor.authorRueda Dominguez, Antonio
dc.contributor.authorLlanos, Marta
dc.contributor.authorGómez Codina, Jose
dc.contributor.authorGarcía Arroyo, Francisco Ramón
dc.contributor.authorCaballero, Dolores
dc.contributor.authorConde, Eulogio
dc.contributor.authorLópez, Andres
dc.contributor.authorProvencio, Mariano
dc.contributor.authorPiris, Miguel A.
dc.date.accessioned2020-11-30T15:34:05Z
dc.date.available2020-11-30T15:34:05Z
dc.date.issued2014-08-01
dc.date.updated2020-11-30T15:34:05Z
dc.description.abstractDiffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous disease entity. Young patients with high-intermediate and high aa-IPI score seem to be good candidates to receive alternative treatments to standard RCHOP-21 including EPOCH-R,2 R-ACVBP+HDT-ASCT3 and upfront autologous stem cell transplantation. Other risk factors can be used to identify patients for the use of more doseintense regimens including bulky disease, interim PET positivity and, importantly, molecular profiles.
dc.format.extent4 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec679858
dc.identifier.issn0390-6078
dc.identifier.pmid24763400
dc.identifier.urihttps://hdl.handle.net/2445/172406
dc.language.isoeng
dc.publisherFerrata Storti Foundation
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3324/haematol.2014.104976
dc.relation.ispartofHaematologica, 2014, vol. 99, num. 8, p. 138-141
dc.relation.urihttps://doi.org/10.3324/haematol.2014.104976
dc.rights(c) Ferrata Storti Foundation, 2014
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Ciències Clíniques)
dc.subject.classificationQuimioteràpia
dc.subject.classificationLimfomes
dc.subject.classificationCèl·lules B
dc.subject.classificationDiagnòstic
dc.subject.classificationCèl·lules mare
dc.subject.otherChemotherapy
dc.subject.otherLymphomas
dc.subject.otherB cells
dc.subject.otherDiagnosis
dc.subject.otherStem cells
dc.titleRisk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Miniatura
Nom:
679858.pdf
Mida:
196.73 KB
Format:
Adobe Portable Document Format
Descarregar

Col·leccions

Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))